Hypercalcaemia and Primary Hyperparathyroidism

  • D. H. Schussheim
  • S. J. Silverberg
Chapter

Abstract

The differential diagnosis of hypercalcaemia is vast, yet over 90% of afflicted patients carry one of two common diagnoses: either primary hyperparathyroidism or malignancy. The former is the most frequent cause of elevated blood calcium levels in a free-living population, while malignancy is the most common diagnosis in hospitalised patients. It is essential to develop a rational strategy for evaluating patients with hypercalcaemia: first, in order to ascertain the cause underlying the abnormality, and second, in order to determine the need for treatment. Not all patients with hypercalcaemia require intervention. In some cases, appropriate therapy is directed to controlling the calcium level per se; in other situations, it is targeted to the underlying disease; and in other clinical situations, no treatment at all is indicated. This chapter will emphasise primary hyperparathyroidism as the central disorder characterised by hypercalcaemia. Other causes of hypercalcaemia will be discussed in less detail thereafter (see Table 3.5).

Keywords

Cancellous Bone Primary Hyperparathyroidism Parathyroid Carcinoma Primary Hyper Osteitis Fibrosa Cystica 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Leite MOR, Correa PHS, Jorgetti V, Batalha JFR, Pereira RC, Mechica JB etal. Dynamic bone histomorphometry in hyperparathyroidism. J Bone Min Res 1990;5(Suppl 2):664a.Google Scholar
  2. 2.
    Meah FA, Tan TT, Taha A, Khalid BA. Primary hyperparathyroidism - a surgical review of 12 cases. Med J Malaya 1991;46:144–9.PubMedGoogle Scholar
  3. 3.
    Dotzenrath C, Goretzki PE, Roher HD. West Germany: still an underdeveloped country in the diagnosis and early treatment of primary hyperparathyroidism? World J Surg 1990;14:660–1.PubMedCrossRefGoogle Scholar
  4. 4.
    Heath III H, Hodgson SF, Kennedy M. Primary hyperparathyroidism: incidence, morbidity and potential economic impact in a community. N Engl J Med 1980;302:189–93.PubMedCrossRefGoogle Scholar
  5. 5.
    Mundy GR, Cove DH, Fisken R. Primary hyperparathyroidism: changes in the pattern of clinical presentation. Lancet 1980;1:1317–20.PubMedCrossRefGoogle Scholar
  6. 6.
    Stenstrom G, Heedman P. Clinical findings in patients with hypercalcaemia: a final investigation based on biochemical screening. Acta Med Scand 1974; 195:473–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Aitken RE, Bartley PC, Bryant SJ, Lloyd HM. The effect of multiphasic biochemical screening on the diagnosis of primary hyperparathyroidism. Aust NZ J Med 1975;5:224–6.Google Scholar
  8. 8.
    Trigonis C, Hamberger B, Farnebo LO, Abarca J, Granberg PO. Primary hyperparathyroidism. Changing trends over fifty years. Acta Chir Scand 1983;149:675–9.Google Scholar
  9. 9.
    Heath III H. Clinical spectrum of primary hyperparathyroidism: evolution with changes in medical practice and technology. J Bone Mineral Res 1991;6(Suppl 2):S63–S70.Google Scholar
  10. 10.
    Melton III LJ. Epidemiology of primary hyperparathyroidism. J Bone Mineral Res 1991;6(Suppl 2):S25–S30.Google Scholar
  11. 11.
    Palmer M, Jakobsson S, Akerstrom G, Ljunghall S. Prevalence of hypercalcaemia in a health survey: a 14-year follow up study of serum calcium values. Eur J Clin Invest 1988;18:39–46.PubMedCrossRefGoogle Scholar
  12. 12.
    Boonstra CE, Jackson CE. Serum calcium survey for hyperparathyroidism: results in 50,000 clinic patients. Am J Clin Pathol 1971;55:523–6.PubMedGoogle Scholar
  13. 14.
    Beard CM, Heath III H, O’Fallon WM, Anderson JA, Earle JD, Melton III LJ. Therapeutic radiation and hyperparathyroidism: a case-control study in Rochester, Minnesota. Arch Intern Med 1989;149:1887–90.PubMedCrossRefGoogle Scholar
  14. 15.
    Cohen J, Gierlowski TC, Schneider AB. A prospective study of hyperparathyroidism in individuals exposed to radiation in childhood. JAMA 1990;264:581–4.PubMedCrossRefGoogle Scholar
  15. 16.
    Shane E, Bilezikian JP. Parathyroid carcinoma. In: Williams CJ, Krikorian JC, Green MR, Raghavan D, editors. Textbook of uncommon cancer. New York: Wiley, 1988;763–71.Google Scholar
  16. 17.
    Bilezikian JP, Silverberg SJ, Shane E, Parisien M, Dempster DW. Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Mineral Res 1991;6(Suppl I):585–9. Google Scholar
  17. 18.
    Silverberg SJ, Shane E, DeLaCruz L. Skeletal disease in primary hyperparathyroidism. J Bone Mineral Res 1989;4:283–91.CrossRefGoogle Scholar
  18. 19.
    Parisien MV, Silverberg SJ, Shane E, de la Cruz L, Lindsay R, Bilezikian JP etal. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab 1990;70:930–38.PubMedCrossRefGoogle Scholar
  19. 20.
    van Doom L, Lips P, Netelenbos JC, Hackengt WHL. Bone histomorphometry and serum intact PTH (I-84) in hyperparathyroid patients. Calcif Tissue Int 1989;44S:N36.Google Scholar
  20. 21.
    Parisien M, Mellish RWE, Silverberg SJ. Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. J Bone Mineral Res 1992;7:913–20.CrossRefGoogle Scholar
  21. 22.
    Christiansen P, Steiniche T, Vesterby A, Mosekilde L, Hessov I, Melsen F. Primary hyperparathyroidism: iliac crest trabecular bone volume, structure, remodelling, and balance evaluated by histo- morphometric methods. Bone 1992;13:144–9.CrossRefGoogle Scholar
  22. 23.
    Parisien M, Cosman F, Mellish RWE, Schnitzer M, Nieves J, Silverberg SJ etal. Bone structure in postmenopausal hyperparathyroid, osteoporotic and normal women. J Bone Min Res 1995;10:1393–9.CrossRefGoogle Scholar
  23. 24.
    Dempster DW, Parisien M, Silverberg SJ, Liang X-G, Schnitzer M, Shen V etal. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 1999; 84:1562–6. 17 proven cases from one clinic. JAMA 1934; 102: 1276–87. PubMedCrossRefGoogle Scholar
  24. 25.
    Wilson RJ, Rao DS, Ellis B, Kleerekoper M, Parfitt AM. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med 1988;109:959–62.PubMedGoogle Scholar
  25. 26.
    Larsson K, Ljunghall S, Krusemo UB, Naessen T, Lindh E, Persson I. The risk of hip fractures in patients with primary hyperparathyroidism: a population-based cohort study with a follow-up of 19 years. J Int Med 1993;234:585–93.CrossRefGoogle Scholar
  26. 27.
    Kenny AM, MacGillivray DC, Pilbeam CC, Crombie HD, Raisz LG. Fracture incidence in postmenopausal women with primary hyperparathyroidism. Surgery 1995;118:109–14.PubMedCrossRefGoogle Scholar
  27. 28.
    Khosla S, Melton LJ, Wermers RA, Crowson CS, O’Fallon WM, Riggs BL. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Mineral Res 1999;14:1700–7.CrossRefGoogle Scholar
  28. 29.
    Silverberg SJ, Shane E, Jacobs TP. Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med 1990;89:327–34.PubMedCrossRefGoogle Scholar
  29. 30.
    Patten BM, Bilezikian JP, Mallette LE, Prince A, Engel WK, Aurbach GD. The neuromuscular disease of hyperparathyroidism. Ann Intern Med 1974;80:182–94.PubMedGoogle Scholar
  30. 31.
    Turken SA, Cafferty M, Silverberg SJ. Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am J Med 1989;87:553–7.PubMedCrossRefGoogle Scholar
  31. 32.
    Joborn C, Rastad J, Stalberg E, Akerstrom G, Ljunghall S. Muscle function in patients with primary hyperparathyroidism. Muscle Nerve 1989;12:87–94.PubMedCrossRefGoogle Scholar
  32. 33.
    Linos DA, vanHeerdan JA, Abboud CF, Edis AJ. Primary hyperparathyroidism and peptic ulcer disease. Arch Surg 1978;113:384–6. PubMedGoogle Scholar
  33. 34.
    Bess MA, Edis AJ, vanHeerden JA. Hyperparathyroidism and pancreatitis. Chance or a causal association? JAMA 1980;243:246–7. PubMedCrossRefGoogle Scholar
  34. 35.
    Bilezikian JP, Aurbach GD, Connor TB. Pseudogout following parathyroidectomy. Lancet 1973; 1:445–7.PubMedCrossRefGoogle Scholar
  35. 36.
    Geelhoed GW, Kelly TR. Pseudogout as a clue and complication in primary hyperparathyroidism. Surgery 1989;106:1036–41.PubMedGoogle Scholar
  36. 37.
    Rapado A. Arterial hypertension and primary hyperparathyroidism. Am J Nephrol 1986;6(Suppl 1):49–50. PubMedCrossRefGoogle Scholar
  37. 38.
    Diamond TW, Botha JR, Wing J, Meyers AM, Kalk WJ. Parathyroid hypertension. A reversible disorder. Arch Intern Med 1986;146:1709–12.Google Scholar
  38. 39.
    Sancho JJ, Rouco J, Riera-Vidal R, Sitges-Serra A. Long-term effects of parathyroidectomy for primary hyperparathyroidism on arterial hypertension. World J Surg 1992;16:732–5.PubMedCrossRefGoogle Scholar
  39. 40.
    Lind L, Jacobsson S, Palmer M, Lithell H, Wengle B, Ljunghall S. Cardiovascular risk factors in primary hyperparathyroidism: a 15-year follow-up of operated and unoperated cases. J Intern Med 1991;230:29–35.PubMedCrossRefGoogle Scholar
  40. 41.
    Stefenelli T, Mayr H, Bergler-Klein J, Globits S, Woloszczuk W, Niederle B. Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Medicine 1993;95:197–202.CrossRefGoogle Scholar
  41. 42.
    Cogan MG, Covery CM, Arieff S, Wisniewski A, Clark OH. Central nervous system manifestations of primary hyperparathyroidism. Am J Med 1978;65:963–70.PubMedCrossRefGoogle Scholar
  42. 43.
    Joborn C, Hetta J, Johansson H. Psychiatric morbidity in primary hyperparathyroidism. World J Surg 1988;12:476–81.PubMedCrossRefGoogle Scholar
  43. 44.
    Joborn C, Hetta J, Frisk P, Palmer M, Akerstrom G, Ljunghall S. Primary hyperparathyroidism in patients with organic brain syndrome. Acta Med Scand 1986;219:91–8.PubMedCrossRefGoogle Scholar
  44. 45.
    Ljunghall S, Jakobsson S, Joborn C, Palmer M, Rastad J, Akerstrom G. Longitudinal studies of mild primary hyperparathyroidism. J Bone Mineral Res 1991;6(Suppl 2):S111–S116.Google Scholar
  45. 46.
    Brown GG, Preisman RC, Kleerekoper MD. Neurobehavioral symptoms in mild primary hyperparathyroidism: related to hypercalcaemia but not improved by parathyroidectomy. He my Ford Med J 1987;35:211–15.Google Scholar
  46. 47.
    Solomon BL, Schaaf M, Smallridge RC. Psychologic symptoms before and after parathyroid surgery. Am J Med 1994;96:101–6.PubMedCrossRefGoogle Scholar
  47. 48.
    Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. The natural history of treated and untreated asymptomatic primary hyperparathyroidism: a ten-year prospective study. N Engl J Med 1999; 341:1249–55.PubMedCrossRefGoogle Scholar
  48. 49.
    Silverberg SJ, Locker FG, Bilezikian JP. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab 1996;81:4007–12.PubMedCrossRefGoogle Scholar
  49. 50.
    Palmer M, Adami H-O, Bergstrom R, Akerstroom G, Ljunghall S. Mortality after surgery for primary hyperparathyroidism: a follow-up of 441 patients operated on from 1956 to 1979. Surgery 1987;102:1–7.PubMedGoogle Scholar
  50. 51.
    Wermers RA, Khosla S, Atkinson EJ, Grant CS, Hodgson SF, O’Fallon M etal. Survival after the diagnosis of hyperparathyroidism. Am J Med 1998;104:115–22.PubMedCrossRefGoogle Scholar
  51. 52.
    Harinarayan DV, Gupta N, Kochupillai N. Vitamin D status in primary hyperparathyroidism in India. Clin Endocrinol 1995;43:351–8.CrossRefGoogle Scholar
  52. 53.
    Luong KVQ, Nguyen LTH. Co-existing hyperthyroidism and hyperparathyroidism with vitamin D-deficient osteomalacia in a Vietnamese immigrant. Endocr Practice 1996;2:250–4.Google Scholar
  53. 54.
    Meng XW, Xing XP, Liu SQ, Zhan ZW. The diagnosis of primary hyperparathyroidism - analysis of 134 cases. Acta Acad Med Sinicae 1994;16:13.Google Scholar
  54. 55.
    Bilezikian JP, Meng X, Shi Y, Silverberg SJ. Primary hyperparathyroidism in women: New York and Beijing (a tale of two cities). Int J Fertility 2000 (in press).Google Scholar
  55. 56.
    Patron P, Gardin J-P, Paillard M. Renal mass and reserve of vitamin D. Determinants in primary hyperparathyroidism. Kidney Int 1987;31:1174–80.Google Scholar
  56. 57.
    Rosol TJ, Capen CC. Mechanisms of cancer-induced hypercalcemia. Lab Invest 1992;67:680.PubMedGoogle Scholar
  57. 58.
    Ratcliffe WA, Hutchesson CJ, Bundred NJ, Ratcliffe JG. Role of assays of parathyroid hormone-related protein in investigation of hypercalcaemia. Lancet 1992;339:164.PubMedCrossRefGoogle Scholar
  58. 59.
    Ikeda K, Ohno H, Hane M, Yokoi H, Okada M, Honma T etal. Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: Evidence for elevated levels in plasma from patients with adult T-cell leukaemia/lymphoma and B-cell lymphoma. J Clin Endocrinol Metab 1994;79:5.CrossRefGoogle Scholar
  59. 60.
    Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE. Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med 1980;303:1377–83.PubMedCrossRefGoogle Scholar
  60. 61.
    Mangin M, Ikeda K, Dreyer BE, Broadus AE. Isolation and characterization of the human parathy-roid hormone-like peptide gene. Proc Natl Acad Sci USA 1989;86(7):2408–12.PubMedCrossRefGoogle Scholar
  61. 62.
    Dunbar ME, Wysolmerski JJ, Broadus AE. Parathyroid hormone-related protein: from hypercalcaemia of malignancy to developmental regulatory molecule. Am J Med Sci 1996;312:287–94.PubMedCrossRefGoogle Scholar
  62. 63.
    Juppner H, Abou-Samra AB, Freeman M, Kong XF, Schipani E, Richards J etal. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 1991; 254:1024–6.PubMedCrossRefGoogle Scholar
  63. 64.
    Philbrick WM, Wysolmerski JJ, Galbraith S, Holt E, Orloff JJ, Yang KH etal. Defining roles of parathyroid hormone-related protein in normal physiology. Physiol Rev 1996;76:127–73.PubMedGoogle Scholar
  64. 65.
    Ikeda K, Ogata E. Humoral hypercalcaemia of malignancy: some enigmas on the clinical features. J Cell Biochem 1995;57:384–91.PubMedCrossRefGoogle Scholar
  65. 66.
    Nussbaum SR, Gaz RD, Arnold A. Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for PTH. N Engl J Med 1990;323: 1324–8.PubMedCrossRefGoogle Scholar
  66. 67.
    Stewart AF, Romero R, Schwartz PE, Kohorn EI, Broadus AE. Hypercalcemia associated with gynecologic malignancies: biochemical characterization. Cancer 1982;49(11):2389–94. PubMedCrossRefGoogle Scholar
  67. 68.
    Wimalawansa SJ. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer 1994;73:2223.PubMedCrossRefGoogle Scholar
  68. 69.
    Ling PJ, A’Hern RP, Hardy JR. Analysis of survival following treatment of tumour-induced hyper-calcaemia with intravenous pamidronate (APD). Br J Cancer 1995;72:206–9.PubMedCrossRefGoogle Scholar
  69. 70.
    Rosenthal NR, Insogna KL, Godshall JW, Smalldone L, Waldron JA, Stewart AF. Elevations in circulating l,25(OH)2D in three patients with lymphoma-associated hypercalcemia. J Clin Endocrinol Metab 1985;60:29–33.PubMedCrossRefGoogle Scholar
  70. 71.
    Seymour JF, Gagel RF, Hagemeister FB, Dimopoulos MA, Cabanillas F. Calcitriol production in hypercalcemia and normocalcemia patients with non-Hodgkin lymphoma. Ann Intern Med 1994; 121:633–40.PubMedGoogle Scholar
  71. 72.
    Thompson BM, Mundy GR, Chambers TJ. Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol 1987; 138:775.Google Scholar
  72. 73.
    Cozzolino F, Torcia M, Aldinucci D, Rubartelli A, Miliani A, Shaw AR etal. Production of interleukin- 1 by bone marrow myeloma cells. Blood 1989;74:387–90.Google Scholar
  73. 74.
    Garrett IR, Durie BG, Nedwin GE, Gillespie A, Bringman T, Sabatini M etal. Production of lympho- toxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med 1987;317:526–32.PubMedCrossRefGoogle Scholar
  74. 75.
    Bataille R, Jourdan M, Zhang Xue-Guang, Klein B. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84:2008–11. PubMedCrossRefGoogle Scholar
  75. 76.
    Firkin F, Seymour JF, Watson AM, Grill V, Martin TJ. Parathyroid hormone-related protein in hyper- calcaemia associated with haematological malignancy. Br J Haematol 1996;94:486–92.PubMedCrossRefGoogle Scholar
  76. 77.
    Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD etal. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671.PubMedGoogle Scholar
  77. 78.
    Michigami T, Shimizu N, Williams PJ, Niewolna M, Dallas SL, Mundy GR etal. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(l)-integrin enhances production of osteoclast-stimulating activity. Blood 2000;96:1953.PubMedGoogle Scholar
  78. 79.
    Hjertner O, Torgersen ML, Seidel C, Hjorth-Hansen H, Waage A, Borset M etal. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: A possible role for HGF in myeloma- associated osteolytic bone disease. Blood 1999;94:3883.PubMedGoogle Scholar
  79. 80.
    Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF etal. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544–9.PubMedCrossRefGoogle Scholar
  80. 81.
    Valentin-Opran A, Eilon G, Saez S, Mundy GR. Estrogens and anti-estrogens stimulate release of bone resorbing activity in cultured human breast cancer cells. J Clin Invest 1985;75:726.PubMedCrossRefGoogle Scholar
  81. 82.
    Winnacker JL, Becker KL, Katz S. Endocrine aspects of sarcoidosis. N Engl J Med 1968;278:483–92.PubMedCrossRefGoogle Scholar
  82. 83.
    Abbasi AA, Chemplavil JK, Farah S, Muller BF, Arnstein AR. Hypercalcemia in active pulmonary tuberculosis. Ann Intern Med 1979;90:324–8.PubMedGoogle Scholar
  83. 84.
    Stoeckle JD, Hardy HL, Weber AL. Chronic beryllium disease. Long-term follow-up of sixty cases and selective review of the literature. Am J Med 1969;46:545–61. PubMedCrossRefGoogle Scholar
  84. 85.
    Lee JC, Catanzaro A, Parthemore JG, Roach B, Deftos LJ. Hypercalcemia in disseminated coccid-ioidomycosis. N Engl J Med 1977;297:431–3.PubMedCrossRefGoogle Scholar
  85. 86.
    Murray JJ, Heim CR. Hypercalcemia in disseminated histoplasmosis. Aggravation by vitamin D. Am J Med 1985;78(5):881–4.Google Scholar
  86. 87.
    Kantarjian HM, Saad MF, Estey EH, Sellin RV, Samaan NA. Hypercalcemia in disseminated candidiasis. Am J Med 1983;74(4):721–4.PubMedCrossRefGoogle Scholar
  87. 88.
    Jurney TH. Hypercalcemia in a patient with eosinophilic granuloma. Am J Med 1984;76(3):527–8.PubMedCrossRefGoogle Scholar
  88. 89.
    Kozeny GA, Barbato AL, Bansal VK, Vertuno LL, Hano JE. Hypercalcemia associated with silicone- induced granulomas. N Engl J Med 1984;311(17):1103–5.PubMedCrossRefGoogle Scholar
  89. 90.
    Edelson GW, Talpos GB, Bone III HG. Hypercalcemia associated with Wegener–s granulomatosis and hyperparathyroidism: etiology and management. Am J Nephrol 1993;13(4):275–7.PubMedCrossRefGoogle Scholar
  90. 91.
    Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin’s disease and non-Hodgkin’s lymphomas. Blood 1993;82(5): 1383–94.PubMedGoogle Scholar
  91. 92.
    Studdy PR, Bird R, Neville E, James DG. Biochemical findings in sarcoidosis. J Clin Pathol 1980; 33:528–33.PubMedCrossRefGoogle Scholar
  92. 93.
    Insogna KL, Dreyer BE, Mitnick M, Ellison AF, Broadus AE. Enhanced production rate of 1,25- dihydroxyvitamin D in sarcoidosis. J Clin Endocrinol Metab 1988;66(1):72–5. PubMedCrossRefGoogle Scholar
  93. 94.
    Barbour GL, Coburn JW, Slatopolsky E, Norman AW, Horst RL. Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. N Engl J Med 1981;305(8):440–3.PubMedCrossRefGoogle Scholar
  94. 95.
    Adams JS, Sharma OP, Gacad MA, Singer FR. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest 1983;72(5): 1856–60.PubMedCrossRefGoogle Scholar
  95. 96.
    Zeimer HJ, Greenaway TM, Slavin J, Hards DK, Zhou H, Doery JC etal. Parathyroid hormone-related protein in sarcoidosis. Am J Pathol 1998; 152:17.PubMedGoogle Scholar
  96. 97.
    Adams JS, Gacad MA, Characterization of 1 hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis. J Exp Med 1985;161:755–65.PubMedCrossRefGoogle Scholar
  97. 98.
    Adams JS, Diz MM, Sharma OP. Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Intern Med 1989;111:437–8.PubMedGoogle Scholar
  98. 99.
    Adams JS, Sharma OP, Diz MM, Endres DB. Ketoconazole decreases the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia. J Clin Endocrinol Metab 1990;70:1090–5.PubMedCrossRefGoogle Scholar
  99. 100.
    St-Arnaud R, Messerlian S, Moir JM, Omdahl JL, Glorieux FH. The 25-hydroxyvitamin D 1- alpha-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) diseases locus. J Bone Min Res 1997;12:1552–9.CrossRefGoogle Scholar
  100. 101.
    Marx SJ, Attie MF, Levine MA, Speigel AM, Downs RW Jr, Lasker RD. The hypocalciuric or benign variant of familial hypecalcemia: clinical and biochemical features in fifteen kindreds. Medicine (Baltimore) 1981;60:397–412.CrossRefGoogle Scholar
  101. 102.
    Brown EM. Physiology and pathophysiology of the extracellular calcium-sensing receptor. Am J Med 1999;106:238–53.PubMedCrossRefGoogle Scholar
  102. 103.
    Cole DE, Janicic N, Salisbury SR, Hendy GN. Neonatal severe hyperparathyroidism, secondary hyperparathyroidism, and familial hypocalciuric hypercalcemia: Multiple different phenotypes associated with an inactivation ALU insertion mutation of the calcium-sensing receptor gene. Am J Med Genet 1997;71:202.PubMedCrossRefGoogle Scholar
  103. 104.
    Davies M, Klimiuk PS, Adams PH, Lumb GA, Large DM, Anderson DC. Familial hypocalciuric hypercalcaemia and acute pancreatitis. Br Med J 1981;282:1023.CrossRefGoogle Scholar
  104. 105.
    Orwoll ES. The milk-alkali syndrome: current concepts. Ann Intern Med 1982;97(2):242–8.PubMedGoogle Scholar
  105. 106.
    Muldowney WP, Mazbar SA. Rolaids-yogurt syndrome: a 1990s version of milk-alkali syndrome. Am J Kidney Dis 1996;27(2):270–2.PubMedCrossRefGoogle Scholar
  106. 107.
    Selby PL, Davies M, Marks SJ, Mawer EB. Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate. Clin Endocrinol (Oxf) 1995;43:531–6.CrossRefGoogle Scholar
  107. 108.
    Ragavan VV, Smith JE, Bilezikian JP. Vitamin A toxicity and hypercalcemia. Am J Med Sci 1982; 283:161–4.PubMedCrossRefGoogle Scholar
  108. 109.
    Christensson T, Hellstrom K, Wengle B. Hypercalcemia and primary hyperparathyroidism. Prevalence in patients receiving thiazides as detected in a health screen. Arch Intern Med 1977;137:1138–42.Google Scholar
  109. 110.
    Haden ST, Stoll AL, McCormick S, Scott J, Fuleihan G el-H. Alterations in parathyroid dynamics in lithium-treated subjects. J Clin Endocrinol Metab 1997;82(9):2844–8.Google Scholar
  110. 111.
    Spiegel AM, Rudorfer MV, Marx SJ, Linnoila M. The effect of short-term lithium administration on suppressibility of parathyroid hormone secretion by calcium in vivo. J Clin Endocrinol Metab 1984;59(2):354–7.PubMedCrossRefGoogle Scholar
  111. 112.
    Nordenstrom J, Elvius M, Bagedahl-Strindlund M, Zhao B, Torring O. Biochemical hyperparathy-roidism and bone mineral status in patients treated long-term with lithium. Metabolism 1994;43(12): 1563–7.PubMedCrossRefGoogle Scholar
  112. 113.
    Legha SS, Powell K, Buzdar AU, Blumenschein GR. Tamoxifen-induced hypercalcemia in breast cancer. Cancer 1981;47(12):2803–6.PubMedCrossRefGoogle Scholar
  113. 114.
    McPherson ML, Prince SR, Atamer ER, Maxwell DB, Ross-Clunis H, Estep HL. Theophylline-induced hypercalcemia. Ann Intern Med 1986;105(1):52–4. PubMedGoogle Scholar
  114. 115.
    Knox JB, Demling RH, Wilmore DW, Sarraf P, Santos AA. Hypercalcemia associated with the use of human growth hormone in an adult surgical intensive care unit. Arch Surg 1995;130(4):442–5.PubMedGoogle Scholar
  115. 116.
    Saunders MP, Salisbury AJ, O’Byrne KJ, Long L, Whitehouse RM, Talbot DC etal. A novel cyclic adenosine monophosphate analog induces hypercalcemia via production of 1,25-dihydroxyvitamin D in patients with solid tumors. J Clin Endocrinol Metab 1997;82(12):4044–8.PubMedCrossRefGoogle Scholar
  116. 117.
    Gayet S, Ville E, Durand JM, Mars ME, Morange S, Kaplanski G etal. Foscarnet-induced hyper-calcaemia in AIDS. AIDS 1997;11(8):1068–70. PubMedGoogle Scholar
  117. 118.
    Burman KD, Monchik JM, Earll JM, Wartofsky L. Ionized and total serum calcium and parathyroid hormone in hyperthyroidism. Ann Intern Med 1976;84(6):668–71.PubMedGoogle Scholar
  118. 119.
    Muls E, Bouillon R, Boelaert J, Lamberigts G, Van Imschoot S, Daneels R etal. Etiology of hyper-calcemia in a patient with Addison’s disease. Calcif Tissue Int 1982;34(6):523–6.PubMedCrossRefGoogle Scholar
  119. 120.
    Stewart AF, Hoecker JL, Mallette LE, Segre GV, Amatruda Jr TT, Vignery A. Hypercalcemia in pheochromocytoma. Evidence for a novel mechanism. Ann Intern Med 1985;102(6):776–9.Google Scholar
  120. 121.
    Venkatesh S, Vassilopoulou-Sellin R, Samaan NA. Somatostatin analog: use in the treatment of vipoma with hypercalcemia. Am J Med 1989;87(3):356–7.PubMedCrossRefGoogle Scholar
  121. 122.
    Stewart AF, Adler M, Byers CM, Segre GV, Broadus AE. Calcium homeostasis in immobilization: an example of resorptive hypercalciuria. N Engl J Med 1982;306(19): 1136–40.PubMedCrossRefGoogle Scholar
  122. 123.
    Meythaler JM, Tuel SM, Cross LL. Successful treatment of immobilization hypercalcemia using calcitonin and etidronate. Arch Phys Med Rehabil 1993;74(3):316–19.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2002

Authors and Affiliations

  • D. H. Schussheim
  • S. J. Silverberg

There are no affiliations available

Personalised recommendations